Displaying 321 - 340 of 1535
Zero Gravity Skin (Perfectio medical devices)
FTC Requires Veterinary Service Providers Compassion First and National Veterinary Associates to Divest Assets in Three Local Markets
FTC Acts to Stop Two Companies from Making Unproven Bone and Joint Claims
FTC, FDA Sign Joint Statement Promoting Competition in Markets for Biologics
Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace
Statement of the FTC Chairman Regarding Announcement that Aveanna Healthcare and Maxim Healthcare Services have Terminated Their Acquisition Agreement
FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim
Illumina Inc./Pacific Biosciences of California, Inc., In the Matter of
The Federal Trade Commission authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California, alleging in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing systems by extinguishing PacBio as a nascent competitive threat. The Commission vote to issue the administrative complaint and to authorize staff to seek a temporary restraining order and preliminary injunction was 5-0. On Jan. 2, 2020, the parties abandoned the transaction.
FTC Comments to State Legislatures in Kansas and Ohio Encourage Granting Advanced Practice Registered Nurses Full Practice Authority
FTC Staff Comment to the Kansas House of Representatives Concerning Kansas House Bill 2412
FTC Staff Comment to the Ohio House of Representatives Concerning Ohio House Bill 177
Statement of Gail Levine, Deputy Director of FTC Bureau of Competition, Regarding the Announcement that Illumina Inc. has Abandoned Its Proposed Acquisition of Pacific Biosciences of California
FTC Challenges Illumina’s Proposed Acquisition of PacBio
Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.
Displaying 321 - 340 of 1535